Compare CION & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CION | SRZN |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.2M | 276.3M |
| IPO Year | 2011 | 2020 |
| Metric | CION | SRZN |
|---|---|---|
| Price | $6.75 | $29.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.75 | ★ $47.50 |
| AVG Volume (30 Days) | 291.1K | ★ 570.9K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | ★ 18.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,477,000.00 |
| Revenue This Year | N/A | $208.89 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.83 | $11.39 |
| 52 Week High | $10.40 | $37.83 |
| Indicator | CION | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 58.65 |
| Support Level | $6.55 | $23.31 |
| Resistance Level | $7.27 | $28.78 |
| Average True Range (ATR) | 0.20 | 2.70 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 76.67 | 73.14 |
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).